P045 Lenticlair™ 1: A phase 1/2 trial evaluating the safety, tolerability and efficacy of an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF ineligible for CFTR modulators

Saved in:

Bibliographic Details
Published in	Journal of cystic fibrosis Vol. 23; p. S80
Main Authors	Davies, J.C., Mall, M.A., Polineni, D., Donaldson, S.H., Fajac, I., Jain, R., Rubin, B.K., Boyd, A.C., Gill, D.R., Griesenbach, U., Hyde, S.C., McLachlan, G., Avis, M., Diefenbach, C., Sigmund, R., Seibold, W., Gupta, A., Alton, E.
Format	Journal Article
Language	English
Published	Elsevier B.V 01.06.2024
Online Access	Get full text

Loading…

More Information
ISSN:	1569-1993 1873-5010
DOI:	10.1016/S1569-1993(24)00350-3